← Leaderboards
Andrew Martin Bellinger
Lyndra Therapeutics, Inc.
$10,090,927
Attributed
$10,090,927
Total exposure
5
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $4.3M · FY2016–20$5M$3.8M$2.5M$1.3M$0
'16
'17
'18
'19
'20
Funding mix
By agency
NIH$10,090,927 · 5
By mechanism
R01$5,243,447 · 1
UG3$2,822,480 · 1
R44$1,500,000 · 1
R43$525,000 · 2
Top collaborators
No co-investigators on record.
Most similar at Lyndra Therapeutics, Inc.
Same institution · by research overlap
- Richard Scranton$12,106,230
- Stephen Zale$5,700,018
- Patrick Boen$8,679,033
Others in their field
Top investigators on “Polymers”
- Marc A Hillmyer · University Of Minnesota-Twin Cities$45,350,238
- Michael F Rubner · Massachusetts Institute Of Technology$44,168,921
- Nicholas Hud · Emory University$41,051,104
- Timothy P Lodge · Gordon Research Conferences$40,942,324
- Eric Baer · Case Western Reserve University$37,476,250
- Robert S Langer · Massachusetts Institute Of Technology$29,222,504
Research focus
PolymersPharmaceutical PreparationsResidenceFormulationBaseStomachDosage FormsOralDoseMeltingDrug KineticsInjectableAnimal ModelRegimenCanis FamiliarisKineticsHourCapsuleDrug Delivery SystemsGrantFda ApprovedNovel TherapeuticsIn VitroIvermectin
Grant awards (10)
Development of Ultra Long-Acting Oral HIV Therapies$1,272,821
R01 · FY2020 · AI · contact PI
Development of Ultra Long-Acting Oral HIV Therapies$1,323,542
R01 · FY2019 · AI · contact PI
An ultra-long-acting oral treatment for opioid use disorder$278,504
UG3 · FY2019 · DA · contact PI
An ultra-long-acting oral treatment for opioid use disorder$2,543,976
UG3 · FY2018 · DA · contact PI
Development of Ultra Long-Acting Oral HIV Therapies$1,323,542
R01 · FY2018 · AI · contact PI
An Oral Ultra Long-Acting Ivermectin for Malaria Elimination$452,399
R44 · FY2018 · TR · contact PI
Development of Ultra Long-Acting Oral HIV Therapies$1,323,542
R01 · FY2017 · AI · contact PI
An Oral Ultra Long-Acting Ivermectin for Malaria Elimination$1,047,601
R44 · FY2017 · TR · contact PI
Novel 3D Printed Architectures for Oral Long-acting Drug Delivery Systems$225,000
R43 · FY2017 · EB · contact PI
An Oral Long-Acting Doxycycline for Onchocerciasis Eradication: Process Improvement for Small Batch Manufacturing$300,000
R43 · FY2016 · AI · contact PI